Tag: Esprit BTK
US FDA approves Abbott’s longer-length Esprit for severe PAD
The US Food and Drug Administration (FDA) has approved Abbott’s new longer-length Esprit BTK system for the treatment of chronic limb-threatening ischaemia (CLTI).
The longer-length...
Three-year data support drug-eluting resorbable scaffold as “durable, effective endovascular treatment...
Three-year data from the LIFE-BTK randomised controlled trial, presented today at the 2025 Vascular Interventional Advances (VIVA) conference (2–5 November, Las Vegas, USA), demonstrate the...
Two-year LIFE-BTK data show sustained benefits of drug-eluting resorbable scaffold for...
Presented today, late-breaking data from the second year of the LIFE-BTK clinical trial demonstrate the long-term effectiveness of the US Food and Drug Administration...
TCT 2024: Drug-eluting resorbable scaffold proves cost effective at one year...
A retrospective economic analysis of the LIFE-BTK trial has demonstrated the one-year cost-effectiveness of an everolimus-eluting resorbable scaffold over angioplasty for the treatment of...
